ArticleJournal of gynecologic oncology2017

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.

Tadaaki Nishikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.